

PATENT
USSN 08/974,584
015389-002950US
018/206p2

APPENDIX C

Other patents and applications

Recombinant hTRT	U.S. Patent 6,475,789; U.S. Patent 6,261,836; U.S. Patent 6,617,110; U.S. Patent 6,808,880; U.S. Patent 6,921,664; U.S. Patent 6,927,285; U.S. Patent 7,005,262; USSN 09/843,676 (allowed); USSN 08/974,584; USSN 09/432,503; USSN 09/721,477; USSN 09/721,506; USSN 10/053,758; USSN 10/044,692; USSN 10/877,022; USSN 10/877,124; USSN 10/044,539; USSN 10/877,146; USSN 11/207,078
hTRT variants	U.S. Patent 6,337,200; USSN 09/990,080
TRT from single cell ciliates	U.S. Patent 6,093,809; U.S. Patent 6,166,178; U.S. Patent 6,309,867
Mouse TRT	U.S. Patent 6,767,719; USSN 10/862,698
Telomerase holoenzyme purified from cells having telomerase activity	U.S. Patent 5,968,506; U.S. Patent 6,261,556; U.S. Patent 6,517,834; U.S. Patent 6,545,133; U.S. Patent 6,787,133; USSN 10/811,033
Use of recombinant hTRT in vaccine formulations	U.S. Patent 6,440,735; USSN 10/208,243; USSN 10/602,441
hTRT promoter	U.S. Patent 6,610,839; U.S. Patent 6,777,203; USSN 10/325,810; USSN 10/674,836
hTRT antisense oligonucleotides	U.S. Patent 6,444,650; U.S. Patent 6,627,619; USSN 10/637,443

**RECEIVED
CENTRAL FAX CENTER**

MAR 14 2006

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being transmitted to the U.S. Patent & Trademark Office
in accordance with 37 CFR § 1.6(d) on the date indicated.

Name

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: T. Cech et al.

Art Unit: 1634

Filing Date: Nov. 19, 1997

Examiner: Carla Myers, Ph.D.

Serial No: 08/974,584

Docket: 015389-002950US
018/206p2Title: AMINO ACID MOTIFS THAT IDENTIFY
TELOMERASE REVERSE TRANSCRIPTASE**DECLARATION UNDER 37 CFR § 1.132****CALVIN B. HARLEY, Ph.D.**Commissioner for Patents
Alexandria VA 22313

Dear Sir:

I, CALVIN HARLEY, do hereby declare as follows:

I am the Chief Scientific Officer at Geron Corporation, and coinventor on the patent
application referred to above.

I understand the Examiner has asked questions relating to the sequences described and
claimed in U.S. Patent 6,093,809, which was filed on May 6, 1997.

PATENT
USSN 10/053,758
Docket 002980US; 018/183

This Patent describes the cloning and sequencing of genes for telomerase reverse transcriptase obtained from several single-celled ciliates, and from human cells. The human TRT sequence was obtained through a collaboration between Thomas Cech, Joachim Lingner, and Toru Nakamura of the University of Colorado, and Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, and William Andrews at Geron Corporation.

Even though various TRT sequences are disclosed, the Patent only claims SEQ. ID NO:1, which is the nucleic acid sequence of TRT for *Euplotes aedicaulatus*. This sequence is considerably less than 50% identical to human TRT at the amino acid level. The *Euplotes* sequence was deduced by Thomas Cech and Joachim Lingner, the named inventors on this patent, without substantive contribution from the other scientists listed above.

I hereby declare that all statements made in this Declaration of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

2006.02.28
Date

Calvin B. Harley
Calvin B. Harley, Ph.D.
Menlo Park, CA